Biotech commercialization should be treated as an engineering discipline
Published in Journal of Diabetes Science and Technology on 2026-08-25.
Summary, written here
The publisher lists no abstract for this article. This summary is ours, written from the article itself.
An editorial arguing that biotech commercialization should be run the way engineering is run, with specifications, measurement, and repeatable process, rather than treated as a series of one-off translational events.
The piece is indexed under artificial intelligence, biotechnology, commercialization, continuous glucose monitoring, diabetes technology, and translational science. The full text is under publisher embargo until August 2027 and is available at the DOI.
Put this to work
Finding application record
Test whether the published finding applies in another setting.
- For
- Practitioners, researchers, founders, and operating leaders.
- What you keep
- A finding application record you can review, revise, and send.
- What counts as sound
- Answers a named decision
- Separates evidence from assumptions
- Includes the strongest contrary case
- Names missing evidence
- Ends with a test, owner, and date
Read the published paper and its limits before acting on the result.
Nothing entered here is stored or sent. Review the prompt before sharing confidential, personal, patient, or privileged information.
Review the prompt
You can leave any field blank. The prompt will mark it as not provided.
If the record survives your review, send the question, evidence, unknowns, and requested next step.